A Phase 2 Clinical Trial To Evaluate Lenalidomide And Obinutuzumab For The Treatment Of Patients With Not Previously Treated Chronic Lymphocytic Leukemia
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2018 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.
- 21 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Mar 2017 Planned initiation date changed from 1 Jun 2017 to 1 Dec 2017.